Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
(7h)
Evommune’s Dupixent-like phase 2 eczema data drive 75% stock rally
(8h)
AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
(8h)
Merck teams up with British medtech to boost vaginal therapeutics delivery system
(11h)
AstraZeneca relaxed about relaxin drug's poor efficacy in phase 2 heart failure trial
(13h)
BioPharma Dive
Novo combination obesity shot meets goal in diabetes trial
(1w)
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
(1w)
GSK walks away from pioneering Wave RNA editing drug
(1w)
Building a robust in-process testing plan for cell therapy manufacturing success
(1w)
Amgen gives up on its once-prized eczema drug
(2w)
Endpoints News
Isomorphic claims major advance with new AI drug design engine
(2h)
ILiAD raises $115M round to advance whooping cough vaccine
(2h)
AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
(2h)
NIH stops low-dose Xarelto arm of large stroke study due to safety concerns
(3h)
Is AstraZeneca on track to meet its $80B revenue target?
(6h)
BioSpace
Webinar: 2026 Hiring Trends and Job Market Signals
(1h)
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
(7h)
Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
(9h)
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
(9h)
REGENXBIO’s Hunter Syndrome Gene Therapy Fails to Win FDA Nod
(10h)
STAT News
We tested the government’s official new AI nutrition tool: Grok
(1h)
Landmark settlement could create new protections for harm reduction under disability law
(3h)
Abridge CTO on Epic and what’s after AI scribing
(3h)
TrumpRx: Hype or real savings?
(7h)
Evommune reports positive mid-stage data for eczema drug
(8h)
BioPharma Trend
Isomorphic Labs Presents an AI Drug Design Engine That Goes Beyond AlphaFold 3
(2h)
Takeda Signs $1.7B AI-Enabled Small Molecule Discovery Deal with Iambic
(1d)
Flagship’s Generate Biomedicines Eyes IPO Amid Reopening Biotech Market Window
(5d)
Anthropic, HHMI, and Allen Institute Launch Claude-Integrated AI Collaborations for Life Science Research
(6d)
Phylo, an Agentic AI Lab, Launches with $13.5M Seed Round, Introduces Biomni Lab
(6d)
Drug Channels
Copay Accumulators and Maximizers in 2025: Popular, Profitable, and Problematic
(11h)
In an Uncertain 340B Environment, Kalderos Offers a Clear Path Forward
(4d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel
(6d)
Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending
(1w)
From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026
(2w)
European Biotechnology Magazine
This Memo sticks: CSL bites in Switzerland for antibody collaboration
(6h)
This Memo sticks: CSL bites in Switzerland for antibody collaboration
(7h)
4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritis
(8h)
Bayer: at least success with coagulation factor XIa in phase 3 of stroke trial
(14h)
Dublin-based Aerska secures $39M Series A to push RNA medicines into the brain
(1d)
Drug Hunter
vimseltinib
(5h)
The New WIZ-kid in Protein Degradation
(1d)
Module 1 Quiz
(1d)
Identification Methods for Drug Repurposing: Case Studies in Neurodegeneration
(4d)
bezuclastinib (CGT9486)
(5d)
Labiotech.EU
Astellas’ “strategic brands” and “primary focuses” after XTANDI
(8h)
Breast cancer treatments heat up: Six therapies poised to transform patient outcomes
(1d)
Top biotech deals in January 2026
(4d)
How Eli Lilly’s biotech collaboration model is rewriting early-stage innovation
(4d)
The biggest biotech funding rounds in January 2026
(6d)
Bio IT World
Trends from the Trenches: What Lies Ahead in Bioinvestment
(16h)
The Role of the Statistical Programmer is Evolving: Here’s How It’s Changing and What That Means for Pharmaceutical Companies
(4d)
PacBio Sells Their Short-Read IP to Illumina
(1w)
Unlocking the Dangers of Disrupted Sleep
(1w)
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
(2w)
GEN News
ALS and Dementia Linked to Bacterial Sugar via Gut–Brain Axis
(1h)
How Long COVID-Related Brain Changes May Link to Alzheimer’s Disease
(1h)
Gator Bio and Hudson Lab Display Antibody Discovery Automation Solution at SLAS
(2h)
Data-Driven Strategies for Addressing Bispecific Antibody Purification Challenges
(3h)
Opentrons Uses Nvidia Tech to Build Training Data That Powers Physical AI in the Lab
(1d)
Cure Today
Keytruda Combo Approved for Platinum-Resistant Ovarian Cancer
(1h)
From Missed Signs to Second Chances After a Liver Cancer Diagnosis
(1h)
Chris Draft Shares Steps to Help Patients Regain Control After Cancer
(2h)
Seeking a Dose of Hope Amidst Cancer
(4h)
FDA Fast Track Designation Highlights New Option in Advanced Liver Cancer
(6h)
Contract Pharma
Waters Completes Combination With BD Biosciences, Diagnostic Solutions Businesses
(1d)
Bruker Introduces Label-Free Characterization Platform for Nanoscale Bioparticles
(1d)
Innovent and Lilly’s Seventh Collaboration Sets Model to Accelerate Pipeline Development
(1d)
PharmaEssentia to Establish a Manufacturing Subsidiary in Puerto Rico
(1d)
Fresenius Kabi, Phlow Partner to Onshore the Manufacture of Epinephrine Injection in the U.S.
(1d)
Pharma Times
AstraZeneca bladder cancer therapy wins NICE backing
(12h)
Head masters
(12h)
Strong clinical data for Breye lead asset danegaptide
(1d)
EHP Awards triumph
(1d)
Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
(1w)
Medcity News
Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis
(1h)
Lilly’s Chief Information & Digital Officer: AI Use Goes Far Beyond Just Drug Discovery
(2h)
Solace Health Reaches Unicorn Status by Taking the ‘Homework’ Out of Care Navigation
(3h)
From Pandemic Urgency to Practical Impact: How Diagnostics Investment Priorities Are Evolving
(7h)
Top ATP Tests for Effective Sanitation and Hygiene Monitoring
(8h)
Chemical & Engineering News
EPA reapproves dicamba use, despite MAHA opposition and previous court bans
(4h)
Feb. 10 Business Watch: Biotech IPOs are back; FMC may soon be for sale
(4h)
Obituary: Lal Vishwakarma
(7h)
Obituary: Lal Vishwakarma
(7h)
Royal Society of Chemistry awards Carolyn Bertozzi Honorary Fellowship
(8h)
The Pharma Letter
Kailera and Hengrui report ribupatide delivers 12.1% weight loss at 26 weeks
(5h)
Novo Nordisk commences legal action against Hims & Hers
(5h)
AstraZeneca’s Imfinzi wins NICE nod as first perioperative IO treatment for MIBC
(6h)
ICER releases evidence report on therapies for IgA nephropathy
(6h)
FDA accepts Takeda’s oveporexton NDA for priority review
(7h)
Targeted Oncology
Analysis Reveals Survival Gap, Racial Disparities in Ovarian Cancer Research
(5d)
Addressing the Overlooked: A New Approach to Treatment-Related High-Risk MDS
(5d)
Balancing Efficacy and Toxicity of Oral SERDs in Breast Cancer
(6d)
FDA Expands Approval of Aptima HPV Assay for Cervical Cancer Primary Screening
(6d)
MDT Boosts Survival Outcomes in Oligometastatic Prostate Cancer
(6d)
MedWatch
Former FDA chief backs Novo Nordic against Hims & Hers: They've crossed the line
(8h)
AstraZeneca expects robust 2026, led by strong cancer drug demand
(10h)
BII expands beyond Denmark: Launches units in UK and Italy
(11h)
Indian drugmakers ready to pounce as Novo Nordisk's patent expiry looms
(13h)
Novo Nordisk working on response after FDA letter about misleading Wegovy ad
(13h)
In The Pipeline
Gumming Things Up On Purpose
(1h)
Crystals Where There Were None
(5d)
What the Literature is Filling Up With
(6d)
A Complex Cancer-Alzheimer's Connection
(7d)
The 2025 FDA Approvals
(1w)
Pharmaphorum
FDA kicks off review of Takeda's narcolepsy hopeful
(6h)
Kailera stakes a claim to the oral weight loss category
(8h)
Kailera, Hengrui stake claim to oral weight loss category
(8h)
AstraZeneca raises guidance on stellar cancer drugs growth
(9h)
Takeda signs $1.7bn AI alliance with Iambic
(10h)
Drug Discovery Weekly
Charles River and Synthace to advance assay development
(5h)
Emulate showcases organ-chip platform at SLAS2026
(6h)
SLAS2026: Day One Round-Up
(9h)
DDW Highlights: 10 February 2026
(10h)
Collaboration to advance drug enhancing immunotherapy response
(10h)
HIT Consultant
Solace Health Raises $130M to Expand Patient Advocacy Network
(1h)
Garner Health Secures $118M to Reward Top Doctors
(1h)
Midstream Health Partners with CommonSpirit Health to Deploy AI Financial Operations Platform
(7h)
Canary Speech Partners with Intermountain Health to Study Vocal Biomarkers for Multiple Sclerosis
(8h)
The “Agent” Dilemma: How Blockchain Could Save Patient Privacy in a $500B AI Market
(8h)
Insights: Pink Sheet
Sobi Takes Second Shot At EU Gamifant Approval
(2h)
Potential Blockbusters From AstraZeneca And Lilly Now Under EMA Review
(2h)
GLP-1s Likely TrumpRx Savings Focus Over Old, Genericized Products
(4h)
EMA Backs Smarter Tool To Spot Pregnancy‑Related Medicine Risks
(8h)
Pharma Hit With $755m In False Claims Act Recoveries
(1d)
BioXconomy
Experts unveil AI breakthroughs in streamlining regulatory reviews
(5h)
Capsida confirms cause of death in clinical trial fatality for rare genetic disorder
(9h)
Lilly to buy Orna in CAR T deal worth up to $2.4bn
(10h)
Viatris, Septerna, BIO, Takeda name new legal chiefs
(10h)
Generate Biomedicines targets IPO to advance asthma treatment
(13h)
BioCentury
Start-up funding, the perils of compounding, and neuropsych insights — a BioCentury podcast
(21h)
Galux: Scaling AI-designed biologics
(22h)
The next wave of biotech growth — a Perspective
(1d)
Lilly buys Orna, strikes broad pipeline deal with Innovent: Deals Report
(1d)
McKinsey vet Franck Le Deu joins Nisa Leung’s new fund; plus C-suite shuffle at Bicycle
(3d)
SCRIP
Evommune’s Atopic Dermatitis Data Competitive With Dupixent
(30m)
CSL CEO Paul McKenzie Exits With Former Exec Gordon Naylor Stepping In
(4h)
FDA Delivers Regenxbio Another Blow, This Time for RGX-121
(4h)
Aerska Builds Cashpile To Advance Brain Shuttle Tech
(6h)
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity
(7h)